Healthcare Sep 01, 2021 10:57 AM (GMT+8)
On September 1, etern therapeutics, which focuses on the development of "non targeted" drug targets, announced the completion of round B financing. This round of financing is jointly led by Hillhouse venture capital and AstraZeneca CICC medical industry fund, followed by Chenxing venture capital. The existing shareholders Xingze capital, Taifu capital and Nuokai assets continue to make additional investment. The financing will be used to accelerate the construction of protein liquid-liquid phase separation technology platform and continue to promote clinical research and the development of follow-up pipelines.
This text is a result of machine translation.